Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?

Executive Summary

CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.

Advertisement

Related Content

Allergan And Editas Sharpen Their CRISPR Focus On Ocular Drugs
J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?
Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration
UC's CRISPR Licensees Unbowed By Losing Initial US Patent Office Ruling
J.P. Morgan Notebook Day 3: Novartis' Cancer Reorg, AbbVie's Price Pledge, Genentech’s Partnering And More
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
China Surprises With First CRISPR Trial Despite Regulatory Lag, Concerns
Bayer And CRISPR Form Cutting Edge Gene Editing JV
Gene Editing Deal Broadens Vertex's CF Base, Doubles CRISPR's Cash
Can CRISPR Make The Jump To Therapeutics?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel